Table 2

Patient characteristics in the TOFA and BARI groups before and after IPTW

VariablesBefore IPTWAfter IPTW
TOFA, n=156BARI, n=138P valueTOFA, n=153*BARI, n=141*P value
Age (years)58.9±13.257.2±13.60.2558.2±13.458.2±13.30.96
Sex, n (% female)129 (82.7)109 (79.0)0.16126 (82.4)115 (81.6)0.86
Disease duration (month)96 (35–192)77 (24–158)0.16118.5±103.7122.3±120.00.77
Treatment history
MTX use at baseline, n (%)117 (75.0)94 (68.1)0.20112 (73.2)103 (73.1)0.53
Dose, mg/w12.3±3.511.7±3.70.1812.2±3.512.0±3.60.68
Glucocorticoid use at baseline, n (%)20 (12.8)33 (23.9)0.0225 (16.3)24 (17.0)0.88
Dose, mg/day5.0 (2.5–7.5)7.5 (5.0–10.0)0.145 (2.5–6.4)7.5 (2.5–10.0)0.26
bDMARD naïve, n (%)37 (23.7)45 (32.6)0.0943 (28.1)40 (28.4)0.52
Number of previous bDMARDs use, n
1/2/3/4/≥5
38/30/26/19/637/22/17/8/90.2436/27/25/17/538/24/20/9/100.60
JAK inhibitor dose, n (%)10 mg=140 (89.7)4 mg=122 (88.4)10 mg=135 (90.8)4 mg=122 (86.5)
5 mg=16 (10.3)2 mg=16 (11.6)5 mg=10 (9.2)2 mg=19 (13.5)
28-tender joint count9.2±6.19.2±6.70.989.2±6.29.0±6.50.72
28-swollen joint count7.0±4.67.8±5.80.217.3±4.67.3±5.30.89
GH, VAS 0–100 mm53.3±24.152.8±24.60.8652.9±23.352.7±24.30.95
EGA, VAS 0–100 mm44.9±20.847.4±22.00.3145.9±20.745.6±21.40.92
Pain VAS 0–100 mm52.4±24.651.1±26.60.6752.2±24.051.8±25.60.91
DAS28-ESR5.3±1.35.2±1.30.345.4±1.35.2±1.30.29
SDAI27.6±12.927.5±13.30.9427.8±12.826.9±12.60.53
CDAI25.8±11.726.1±12.70.8826.3±11.725.4±11.90.81
HAQ-DI1.3±0.81.2±0.80.121.3±0.81.2±0.70.90
EQ-5D0.6±0.10.6±0.10.430.6±0.10.6±0.10.86
CRP (mg/dL)0.4 (0.1–1.8)0.4 (0.1–1.3)0.640.4 (0.1–1.7)0.4 (0.1–1.6)0.76
ESR (mm/hour)39.4±30.138.2±30.10.7340.4±31.539.4±30.90.80
Rheumatoid factor positive, n (%)121 (77.6)107 (77.5)1.00118 (77.1)107 (75.9)0.89
Rheumatoid factor (U/mL)69.2 (18.6–157.9)51.4 (13.7–150.7)0.3970.3 (18.1–170.4)46.5 (11.4–121.9)0.85
Anti-CCP antibody, n (%)118 (75.6)98 (71.0)0.43115 (75.2)99 (70.2)0.36
Anti-CCP antibody (U/mL)41.7 (5.2–265.8)76.2 (2.6–397.1)0.5645.2 (5.3–272.1)70.6 (1.9–386.4)0.78
MMP-3 (ng/mL)93 (55–264)118 (51–229)0.8286 (53–252)111 (50–234)0.80
  • Data are mean±SD, median (IQR) or number (%) of patients.

  • *The number of subjects changed after IPTW in the calculation; however, the actual number of subjects did not change.

  • BARI, baricitinib; bDMARDs, biological disease-modifying antirheumatic drugs; CCP, cyclic citrullinated peptide; CDAI, Clinical Disease Activity Index; CRP, C reactive protein; DAS, Disease Activity Score; EGA VAS, Evaluator Global Assessment of Disease Activity Visual Analogue Scale; EQ-5D, EuroQol 5 dimension; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire-Disability Index; IPTW, inverse probability of treatment weighting; JAK, Janus kinase; MMP-3, matrix metalloproteinase 3; MTX, methotrexate; SDAI, Simplified Disease Activity Index; TOFA, tofacitinib; GH VAS, patient’s global assessment of disease activity visual analogue scale.